Race Oncology has world class, incredible calibre people in the management and team .
As well as some of the best , top haematology oncologists & renowned medical researchers.
All of these people have many other things they could choose to do with their time and in their work - but choose to be here , wanted to work for Race , to bring bisantrene into full registration as a very good oncology drug.
*This has been very compelling as the aim for all in management and the team who have chosen to join Race Oncology.
They are working for lower salaries & remuneration.
All were and still are confident to accept out of the money options primarily as remuneration for their hard work.
* Recheck the credentials of Prof Borje Andersson , at MD Anderson (Cancer ) Centre - the preeminent Cancer research and treatment facility , 9 of the last 10 years in the whole of America .
He is the inventor of the global standard of care co- treatment given when receiving a bone marrow transplant . He researched and developed it. He has as his life work goal to further increase survival and cure rates in leukaemia patients, *particularly for AML * .
Residual cancer cells , or refractory ( difficult- unresponsive to existing standard oncology treatments or not responsive enough ) cancer , is the reason people die of course from their cancers other than an adverse reaction or illness -if they otherwise can tolerate and respond to treatment & receive a matching marrow transplant .
* Recheck Dr John Cullity’s past achievements and his lead roles in employment . He himself also a top haematology oncologist ( past employment including management of drug acquisitions for Sanofi )
These leading oncologists and specialists as well as our highly qualified and competent Dr Tillet as CFO and dual CEO , & new ex- Johnson and Johnson Asia Pacific CEO as well.
Apart from the huge amount of data held , from over 40 clinical trials , enormous work done - *Bisantrene is a Phase 3 asset** , and had past European registration .
All information , colossal amounts shows proof of efficacy - and people alive today after over 30 years also —says :
•bisantrene works ,
•is very needed ! for dire cancers including AML and breast cancer, and
•exhibits lower , notably less toxicity than the anthracyclines especially doxorubicin.
•safety and dose protocol regimes also fairly well understood .
Ultra advanced situation already with Bisantrene , and Race - 5 years already . Says no one is just going to drop this and walk away . Even for the patents and ownership value of bisantrene RAC is undervalued .
I don’t think this is about ‘odds’ , or averages as you say of which stocks might or might not be successful , or about ‘maybe’ .
The company exists - to succeed .
General Comments / Chat, page-600
-
- There are more pages in this discussion • 11,249 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M |
Open | High | Low | Value | Volume |
$1.66 | $1.69 | $1.57 | $387.6K | 237.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 807 | $1.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.69 | 2376 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 807 | 1.630 |
1 | 4000 | 1.600 |
2 | 2300 | 1.580 |
1 | 636 | 1.570 |
1 | 6000 | 1.560 |
Price($) | Vol. | No. |
---|---|---|
1.690 | 2376 | 1 |
1.735 | 3313 | 1 |
1.750 | 2000 | 1 |
1.790 | 1000 | 1 |
1.800 | 2000 | 1 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |